8-K: SelectQuote Reports Strong Q3 Results, Raises Full-Year Guidance

SelectQuote exceeded expectations for the ninth consecutive quarter, reporting increased revenue and adjusted EBITDA, and raising its full-year guidance.

Summary

• SelectQuote reported a revenue of $376.4 million for the third quarter of fiscal year 2024, a 26% increase compared to $299.4 million in the same quarter of the previous year.
• The company's net income for the quarter was $8.6 million, slightly down from $9.3 million in the third quarter of fiscal year 2023.
• Adjusted EBITDA for the quarter was $46.6 million, up from $44.0 million in the prior year's comparable quarter.
• The company has raised its full-year revenue guidance to a range of $1.25 billion to $1.3 billion, up from the previous range of $1.23 billion to $1.3 billion.
• The full-year net loss is now expected to be between $34 million and $21 million, an improvement from the prior range of $45 million to $22 million.
• Adjusted EBITDA for the full year is projected to be between $100 million and $110 million, increased from the previous range of $90 million to $105 million.
• The Senior segment saw revenue of $204.3 million and adjusted EBITDA of $61.5 million, with 185,716 approved Medicare Advantage policies.
• Healthcare Services revenue was $124.2 million with adjusted EBITDA of $1.6 million, and SelectRx membership exceeded 75,000.
• Life segment revenue was $40.7 million with adjusted EBITDA of $3.1 million, while Auto & Home revenue was $9.1 million with adjusted EBITDA of $3.6 million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong financial results, raised guidance, and positive management commentary. The company's strategic initiatives appear to be paying off, and the future outlook is optimistic.

Positives

• SelectQuote has outperformed expectations for nine consecutive quarters.
• The company's strategic redesign has led to strong and stable operating performance in the Senior segment.
• The Healthcare Services segment achieved positive adjusted EBITDA for the fourth consecutive quarter.
• The company's revenue to customer acquisition cost multiple is strong at over 4x.
• The company has successfully extended the maturity date of $683.8 million of term loans to May 15, 2025.
• The company is on pace to deliver positive operating cash flow and approach free cash flow breakeven for fiscal year 2024.
• The company's per unit economics have improved, with total revenue per MA/MS policy increasing by 31% year-over-year.

Negatives

• The company's net income for the third quarter of fiscal year 2024 was slightly lower than the same quarter of the previous year.
• The Life segment's adjusted EBITDA decreased by 41% in the third quarter of fiscal year 2024 compared to the same period in 2023.
• The company's total operating expenses per MA/MS policy increased by 22% for the twelve months ended March 31, 2024, primarily due to the growth of the SelectRx business.
• The company's cash and cash equivalents decreased from $83.156 million to $37.808 million between June 30, 2023 and March 31, 2024.

Risks

• The company relies on a limited number of insurance carrier partners, and the termination of these relationships could negatively impact the business.
• Changes in health insurance laws and regulations could affect the company's operations.
• Competition from other brokers and insurance carriers could impact the company's market share.
• The company's dependence on lead providers and the ability to convert leads into sales is a risk.
• The company's financial results are subject to seasonality.
• The company's ability to maintain compliance with debt covenants is a risk.
• Cybersecurity breaches or other attacks could disrupt operations and compromise consumer data.
• The company's pharmacy business is subject to risks including manufacturing or supply chain disruptions, access to and demand for prescription drugs, and regulatory changes.

Future Outlook

SelectQuote has raised its full-year revenue guidance to a range of $1.25 billion to $1.3 billion, net loss is expected to be between $34 million and $21 million, and adjusted EBITDA is projected to be between $100 million and $110 million.

Management Comments

• Chief Executive Officer Tim Danker commented, SelectQuote outperformed our own expectations for the 9th consecutive quarter, and the company has never been better positioned to drive shareholder value.
• Mr. Danker concluded, The teams at SelectQuote and our leadership are energized about the successes experienced year-to-date. We have conviction that 2024 will prove to be an inflection point in our companys history, and SelectQuote is poised to leverage our unique healthcare platform to drive attractive returns for our shareholders in the quarters and years ahead.

Industry Context

The results reflect a strong performance in the health insurance brokerage sector, particularly in the Medicare Advantage market, where SelectQuote has a significant presence. The expansion of their Healthcare Services segment, especially SelectRx, indicates a move towards integrated healthcare solutions, which is a growing trend in the industry.

Comparison to Industry Standards

• SelectQuote's revenue growth of 26% year-over-year in Q3 2024 is strong compared to some of its competitors in the insurance brokerage space, such as eHealth, Inc. which has seen more modest growth.
• The company's adjusted EBITDA margin in the Senior segment, exceeding 30%, is a positive indicator of operational efficiency, which is comparable to top performers in the sector.
• The growth of SelectRx and the overall Healthcare Services segment is a strategic move to diversify revenue streams, similar to other companies that are expanding into adjacent healthcare services.
• The company's revenue to customer acquisition cost multiple of 4.2x is a key metric that shows the efficiency of their marketing spend, which is a critical factor for profitability in the industry.
• The lifetime value of commissions per approved Medicare Advantage policy at $995 is a competitive figure, indicating the company's ability to generate value from each policy sold.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and profitability, as well as the raised guidance.
• Employees will benefit from the company's continued growth and success.
• Customers will benefit from the company's expanded healthcare services and product offerings.
• Suppliers and creditors will benefit from the company's improved financial stability.

Next Steps

• The company will continue to focus on growing its Senior and Healthcare Services segments.
• The company will leverage its unique healthcare platform to drive shareholder value.
• The company will continue to monitor and manage its debt obligations.
• The company will host a conference call with the investment community to discuss the results.

Key Dates

Keywords

insurance, Medicare Advantage, healthcare services, SelectRx, adjusted EBITDA, revenue, financial results, Medicare Supplement, life insurance, auto insurance, home insurance